Hope S. Rugo, MD
Professor of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Authored Items
Videos
Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent. Read More ›
Conference Correspondent
Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. Read More ›
Conference Correspondent
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more. Read More ›
Conference Correspondent
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer. Read More ›
Conference Correspondent
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›
Conference Correspondent
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›
Conference Correspondent
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›